Physician profile
Paul D Orr
NPI 1417950221
$1,834.91
in general payments reported to CMS, 2019-2025
28 companies · $178 in 2025
The $178 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $283 · 2020: $350 · 2021: $312 · 2022: $336 · 2023: $197 · 2024: $179 · 2025: $178.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $554.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $554.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $359.32 | 2019-2023 | |
| Pfizer INC. | $183.22 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $118.03 | 2022-2024 | Eliquis |
| Lilly USA, LLC | $112.07 | 2019-2025 | Kisunla |
| Bausch Health US, LLC | $99.52 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $91.86 | 2019-2023 | Xifaxan |
| Amgen INC. | $87.98 | 2019-2025 | Otezla, Repatha, Repatha |
| Amarin Pharma, INC. | $80.70 | 2020-2021 | |
| Allergan, INC. | $76.43 | 2019-2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $76.18 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $68.09 | 2020-2021 | |
| Astellas Pharma US INC | $64.27 | 2019-2024 | Veozah |
| Glaxosmithkline, LLC. | $43.19 | 2020-2024 | Arexvy |
| Eisai INC. | $39.47 | 2020 | |
| Exact Sciences Corporation | $39.19 | 2024-2025 | Cologuard Collection Kit |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Calliditas Therapeutics US INC. | $39.02 | 2025 | Tarpeyo |
| Scilex Pharmaceuticals INC. | $38.02 | 2019 | |
| Almatica Pharma LLC | $37.87 | 2021 | |
| Sanofi Pasteur INC. | $27.51 | 2019-2023 | |
| Novo Nordisk INC | $22.10 | 2025 | |
| Tms Neurohealth Centers INC. | $22.06 | 2025 | Tms Neurohealth Centers INC. |
| Aytu Biopharma, INC. | $18.43 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $17.88 | 2023 | |
| Promius Pharma LLC | $17.01 | 2019 | |
| Phadia US INC. | $14.31 | 2022 | |
| Therapeuticsmd, INC. | $14.10 | 2021 | |
| Merck Sharp & Dohme LLC | $13.87 | 2019 | |
| Novartis Pharmaceuticals Corporation | $13.21 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Orr listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.